Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. ROBO1 is a potential target and spectacular paradigm in the treatment of solid tumors. This study is for evaluation of the safety and efficacy of ROBO1 CAR-NK cell immunotherapy for pancreatic cancer.

开始日期2019-05-01

申办/合作机构

阿茨可利（杭州）医学科技有限公司

NCT03931720 / Unknown status临床1/2期

Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor

Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. ROBO1 is a potential target and spectacular paradigm in the diagnosis and treatment of solid tumors. This study is for evaluation of the safety and efficacy of ROBO1 CAR-NK/T cell immunotherapy for malignant tumors.

开始日期2019-05-01

申办/合作机构

阿思科力（苏州）生物科技有限公司

100 项与 ROBO1 Specific BiCAR-NK/T cells(Asclepius) 相关的临床结果

登录后查看更多信息

100 项与 ROBO1 Specific BiCAR-NK/T cells(Asclepius) 相关的转化医学

登录后查看更多信息

100 项与 ROBO1 Specific BiCAR-NK/T cells(Asclepius) 相关的专利（医药）

登录后查看更多信息

项与 ROBO1 Specific BiCAR-NK/T cells(Asclepius) 相关的文献（医药）

2022-03-16·Cancer investigation4区 · 医学

Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity

4区 · 医学

Article

作者: Liu, Zhi ; Zhang, Pumin ; Lu, Lisheng ; Zhang, Qing ; Liu, Shuang ; Shen, Huijuan ; Zhu, Yangmin ; Peng, Liang ; Wang, Baolei ; Ou, Ruiming ; Zeng, Wanying

Despite high remission rates following chimeric antigen receptor T cell (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL), relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may improve the CAR-T effect. The in vitro and in vivo leukemia model was established, and the anti-tumor effects of BiCAR-T, CD19 CAR-T, CD22 CAR-T, and LoopCAR6 cells were observed. We found that the BiCAR-T cells showed significant cytotoxicity in vitro and in vivo. The CD19/CD22 bivalent CAR provides an opportunity to test whether simultaneous targeting may reduce the risk of antigen loss.

2019-11-01·Anticancer research4区 · 医学

Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of ¹²⁵I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma

4区 · 医学

Article

作者: Lu, Jian ; Sun, Y U ; Xia, Ning ; Hoffman, Robert M ; Chen, Zhijin ; Wang, Zhongmin ; Haopeng, Pang ; Zheng, Yunfeng ; Yang, Zhijian ; Gong, J U ; Liu, Fenju

BACKGROUND/AIM:

The aim of the current study was to investigate the synergistic efficacy of Robo1 bichimeric antigen receptor-natural killer cell (BiCAR-NK) immunotherapy and ¹²⁵I seed brachytherapy in an orthotopic pancreatic cancer mouse model.

MATERIALS AND METHODS:

The orthotopic pancreatic tumor model was established with human pancreatic cancer BxPC-3 cells expressing red fluorescent protein. The mice were treated with ¹²⁵I seed implantation alone or the combination of ¹²⁵I seeds with Robo1-specific CAR-NK cells. To assess tumor inhibition, in vivo fluorescence imaging was conducted. 7 Tesla magnetic resonance (7T-MR) scanning was applied to measure the changes in the metabolic profiles of tumor tissues.

RESULTS:

Tumor size was significantly reduced in the ¹²⁵I and ¹²⁵I +CAR-NK treated group compared to the untreated group (p<0.05). The ¹²⁵I seed +CAR-NK treated group showed significantly higher tumor reduction than ¹²⁵I seed treatment alone (p<0.05). T1 diffusion weighted imaging (T1DWI) sequence showed that the tumors of the ¹²⁵I +BiCAR-NK treated group had a significantly higher grey scale value than the tumors from the untreated control and the group treated with ¹²⁵I seed alone (p<0.05).

CONCLUSION:

Robo1 specific CAR-NK immunotherapy enhances efficacy of ¹²⁵I seed brachytherapy in an orthotopic pancreatic cancer mouse model.

100 项与 ROBO1 Specific BiCAR-NK/T cells(Asclepius) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发癌	临床2期	中国	阿思科力（苏州）生物科技有限公司	2019-05-01
实体瘤	临床2期	中国	阿思科力（苏州）生物科技有限公司	2019-05-01